Loading…

Berberine: A potential adjunct for the treatment of gastrointestinal cancers?

Gastrointestinal cancers are among the most prevalent cancers in the general population. Despite effective early diagnostics and intervention, the gastrointestinal cancer‐related mortality still remains elevated. Berberine (BBR) is a benzyl tetra isoquinoline alkaloid exracted from several plants. B...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cellular biochemistry 2018-12, Vol.119 (12), p.9655-9663
Main Authors: Hesari, AmirReza, Ghasemi, Faezeh, Cicero, Arrigo F. G., Mohajeri, Mohammad, Rezaei, Omid, Hayat, Seyed Mohammad Gheibi, Sahebkar, Amirhossein
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3532-90b40012e0a6bfd9abb088fb500343ec696b9f3bfd9a1c7cc9ffca23d4701c303
cites cdi_FETCH-LOGICAL-c3532-90b40012e0a6bfd9abb088fb500343ec696b9f3bfd9a1c7cc9ffca23d4701c303
container_end_page 9663
container_issue 12
container_start_page 9655
container_title Journal of cellular biochemistry
container_volume 119
creator Hesari, AmirReza
Ghasemi, Faezeh
Cicero, Arrigo F. G.
Mohajeri, Mohammad
Rezaei, Omid
Hayat, Seyed Mohammad Gheibi
Sahebkar, Amirhossein
description Gastrointestinal cancers are among the most prevalent cancers in the general population. Despite effective early diagnostics and intervention, the gastrointestinal cancer‐related mortality still remains elevated. Berberine (BBR) is a benzyl tetra isoquinoline alkaloid exracted from several plants. BBR is nontoxic to human normal cells, but suppresses the growth of different tumor cells: melanoma, epidermoid carcinoma, hepatoma, oral carcinoma, glioblastoma, prostatic carcinoma, and gastric carcinoma. In particular, BBR seems to suppress the proliferation of gastrointestinal cancers in a number of preclinical models. Several mechanisms of action have been hypothesized and demonstrated: immunomodulation, inhibition of topoisomerase enzymes, suppression of the EGF receptor, Her2/neu, and the VEGF receptor, induction of p53, Cip1/p21, Kip1/p27, Rb expression, induction of apoptosis (by regulation of MMPs pathway, caspases, Bax, and Smac/DIABLO), inhibition of arylamin N‐acetyltransferase activity, and regulation of microRNAs expression. The aim of this review is to summarize the pharmacological effects of BBR on animal and human gastrointestinal cancers. This review highlights the potential therapeutic role of berberine in gastrointestinal cancers. We have reviewed the molecular mechanisms of action of this alkaloid and the cellular targets through which berberine might exert its beneficial anti‐tumor effects.
doi_str_mv 10.1002/jcb.27392
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2091235408</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2129471086</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3532-90b40012e0a6bfd9abb088fb500343ec696b9f3bfd9a1c7cc9ffca23d4701c303</originalsourceid><addsrcrecordid>eNp10DtPwzAUBWALgWgpDPwBFIkFhrTXjyYxC2ornipigTmyHRtS5VFsR6j_HtMUBiSmO9xPR0cHoVMMYwxAJislxySlnOyhIQaexixhbB8NIaUQE4rJAB05twIAzik5RAMKmEx5yoboaa6t1LZs9FU0i9at140vRRWJYtU1ykemtZF_15G3Wvg6PKPWRG_CeduWjdfOl03QSjRKW3d9jA6MqJw-2d0Rer29eVncx8vnu4fFbBkrOqUk5iAZhAoaRCJNwYWUkGVGTgEoo1olPJHc0O0Lq1QpbowShBYsBawo0BG66HPXtv3oQou8Lp3SVSUa3XYuJ8AxoVMGWaDnf-iq7WwoHRQmnKUYsiSoy14p2zpntcnXtqyF3eQY8u-N87Bxvt042LNdYidrXfzKn1EDmPTgs6z05v-k_HEx7yO_ABazhOg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2129471086</pqid></control><display><type>article</type><title>Berberine: A potential adjunct for the treatment of gastrointestinal cancers?</title><source>Wiley</source><creator>Hesari, AmirReza ; Ghasemi, Faezeh ; Cicero, Arrigo F. G. ; Mohajeri, Mohammad ; Rezaei, Omid ; Hayat, Seyed Mohammad Gheibi ; Sahebkar, Amirhossein</creator><creatorcontrib>Hesari, AmirReza ; Ghasemi, Faezeh ; Cicero, Arrigo F. G. ; Mohajeri, Mohammad ; Rezaei, Omid ; Hayat, Seyed Mohammad Gheibi ; Sahebkar, Amirhossein</creatorcontrib><description>Gastrointestinal cancers are among the most prevalent cancers in the general population. Despite effective early diagnostics and intervention, the gastrointestinal cancer‐related mortality still remains elevated. Berberine (BBR) is a benzyl tetra isoquinoline alkaloid exracted from several plants. BBR is nontoxic to human normal cells, but suppresses the growth of different tumor cells: melanoma, epidermoid carcinoma, hepatoma, oral carcinoma, glioblastoma, prostatic carcinoma, and gastric carcinoma. In particular, BBR seems to suppress the proliferation of gastrointestinal cancers in a number of preclinical models. Several mechanisms of action have been hypothesized and demonstrated: immunomodulation, inhibition of topoisomerase enzymes, suppression of the EGF receptor, Her2/neu, and the VEGF receptor, induction of p53, Cip1/p21, Kip1/p27, Rb expression, induction of apoptosis (by regulation of MMPs pathway, caspases, Bax, and Smac/DIABLO), inhibition of arylamin N‐acetyltransferase activity, and regulation of microRNAs expression. The aim of this review is to summarize the pharmacological effects of BBR on animal and human gastrointestinal cancers. This review highlights the potential therapeutic role of berberine in gastrointestinal cancers. We have reviewed the molecular mechanisms of action of this alkaloid and the cellular targets through which berberine might exert its beneficial anti‐tumor effects.</description><identifier>ISSN: 0730-2312</identifier><identifier>EISSN: 1097-4644</identifier><identifier>DOI: 10.1002/jcb.27392</identifier><identifier>PMID: 30125974</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Acetyltransferase ; Apoptosis ; Berberine ; cancer ; Cyclin-dependent kinase inhibitor p27 ; DIABLO protein ; ErbB-2 protein ; Gastric cancer ; gastrointestinal tract ; Glioblastoma ; Hepatoma ; Immunomodulation ; Liver cancer ; Melanoma ; miRNA ; Oral carcinoma ; p53 Protein ; Pharmacology ; Prostate cancer ; Tumor cells ; Vascular endothelial growth factor</subject><ispartof>Journal of cellular biochemistry, 2018-12, Vol.119 (12), p.9655-9663</ispartof><rights>2018 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3532-90b40012e0a6bfd9abb088fb500343ec696b9f3bfd9a1c7cc9ffca23d4701c303</citedby><cites>FETCH-LOGICAL-c3532-90b40012e0a6bfd9abb088fb500343ec696b9f3bfd9a1c7cc9ffca23d4701c303</cites><orcidid>0000-0002-8656-1444</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30125974$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hesari, AmirReza</creatorcontrib><creatorcontrib>Ghasemi, Faezeh</creatorcontrib><creatorcontrib>Cicero, Arrigo F. G.</creatorcontrib><creatorcontrib>Mohajeri, Mohammad</creatorcontrib><creatorcontrib>Rezaei, Omid</creatorcontrib><creatorcontrib>Hayat, Seyed Mohammad Gheibi</creatorcontrib><creatorcontrib>Sahebkar, Amirhossein</creatorcontrib><title>Berberine: A potential adjunct for the treatment of gastrointestinal cancers?</title><title>Journal of cellular biochemistry</title><addtitle>J Cell Biochem</addtitle><description>Gastrointestinal cancers are among the most prevalent cancers in the general population. Despite effective early diagnostics and intervention, the gastrointestinal cancer‐related mortality still remains elevated. Berberine (BBR) is a benzyl tetra isoquinoline alkaloid exracted from several plants. BBR is nontoxic to human normal cells, but suppresses the growth of different tumor cells: melanoma, epidermoid carcinoma, hepatoma, oral carcinoma, glioblastoma, prostatic carcinoma, and gastric carcinoma. In particular, BBR seems to suppress the proliferation of gastrointestinal cancers in a number of preclinical models. Several mechanisms of action have been hypothesized and demonstrated: immunomodulation, inhibition of topoisomerase enzymes, suppression of the EGF receptor, Her2/neu, and the VEGF receptor, induction of p53, Cip1/p21, Kip1/p27, Rb expression, induction of apoptosis (by regulation of MMPs pathway, caspases, Bax, and Smac/DIABLO), inhibition of arylamin N‐acetyltransferase activity, and regulation of microRNAs expression. The aim of this review is to summarize the pharmacological effects of BBR on animal and human gastrointestinal cancers. This review highlights the potential therapeutic role of berberine in gastrointestinal cancers. We have reviewed the molecular mechanisms of action of this alkaloid and the cellular targets through which berberine might exert its beneficial anti‐tumor effects.</description><subject>Acetyltransferase</subject><subject>Apoptosis</subject><subject>Berberine</subject><subject>cancer</subject><subject>Cyclin-dependent kinase inhibitor p27</subject><subject>DIABLO protein</subject><subject>ErbB-2 protein</subject><subject>Gastric cancer</subject><subject>gastrointestinal tract</subject><subject>Glioblastoma</subject><subject>Hepatoma</subject><subject>Immunomodulation</subject><subject>Liver cancer</subject><subject>Melanoma</subject><subject>miRNA</subject><subject>Oral carcinoma</subject><subject>p53 Protein</subject><subject>Pharmacology</subject><subject>Prostate cancer</subject><subject>Tumor cells</subject><subject>Vascular endothelial growth factor</subject><issn>0730-2312</issn><issn>1097-4644</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp10DtPwzAUBWALgWgpDPwBFIkFhrTXjyYxC2ornipigTmyHRtS5VFsR6j_HtMUBiSmO9xPR0cHoVMMYwxAJislxySlnOyhIQaexixhbB8NIaUQE4rJAB05twIAzik5RAMKmEx5yoboaa6t1LZs9FU0i9at140vRRWJYtU1ykemtZF_15G3Wvg6PKPWRG_CeduWjdfOl03QSjRKW3d9jA6MqJw-2d0Rer29eVncx8vnu4fFbBkrOqUk5iAZhAoaRCJNwYWUkGVGTgEoo1olPJHc0O0Lq1QpbowShBYsBawo0BG66HPXtv3oQou8Lp3SVSUa3XYuJ8AxoVMGWaDnf-iq7WwoHRQmnKUYsiSoy14p2zpntcnXtqyF3eQY8u-N87Bxvt042LNdYidrXfzKn1EDmPTgs6z05v-k_HEx7yO_ABazhOg</recordid><startdate>201812</startdate><enddate>201812</enddate><creator>Hesari, AmirReza</creator><creator>Ghasemi, Faezeh</creator><creator>Cicero, Arrigo F. G.</creator><creator>Mohajeri, Mohammad</creator><creator>Rezaei, Omid</creator><creator>Hayat, Seyed Mohammad Gheibi</creator><creator>Sahebkar, Amirhossein</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QP</scope><scope>7QR</scope><scope>7T7</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8656-1444</orcidid></search><sort><creationdate>201812</creationdate><title>Berberine: A potential adjunct for the treatment of gastrointestinal cancers?</title><author>Hesari, AmirReza ; Ghasemi, Faezeh ; Cicero, Arrigo F. G. ; Mohajeri, Mohammad ; Rezaei, Omid ; Hayat, Seyed Mohammad Gheibi ; Sahebkar, Amirhossein</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3532-90b40012e0a6bfd9abb088fb500343ec696b9f3bfd9a1c7cc9ffca23d4701c303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Acetyltransferase</topic><topic>Apoptosis</topic><topic>Berberine</topic><topic>cancer</topic><topic>Cyclin-dependent kinase inhibitor p27</topic><topic>DIABLO protein</topic><topic>ErbB-2 protein</topic><topic>Gastric cancer</topic><topic>gastrointestinal tract</topic><topic>Glioblastoma</topic><topic>Hepatoma</topic><topic>Immunomodulation</topic><topic>Liver cancer</topic><topic>Melanoma</topic><topic>miRNA</topic><topic>Oral carcinoma</topic><topic>p53 Protein</topic><topic>Pharmacology</topic><topic>Prostate cancer</topic><topic>Tumor cells</topic><topic>Vascular endothelial growth factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hesari, AmirReza</creatorcontrib><creatorcontrib>Ghasemi, Faezeh</creatorcontrib><creatorcontrib>Cicero, Arrigo F. G.</creatorcontrib><creatorcontrib>Mohajeri, Mohammad</creatorcontrib><creatorcontrib>Rezaei, Omid</creatorcontrib><creatorcontrib>Hayat, Seyed Mohammad Gheibi</creatorcontrib><creatorcontrib>Sahebkar, Amirhossein</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cellular biochemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hesari, AmirReza</au><au>Ghasemi, Faezeh</au><au>Cicero, Arrigo F. G.</au><au>Mohajeri, Mohammad</au><au>Rezaei, Omid</au><au>Hayat, Seyed Mohammad Gheibi</au><au>Sahebkar, Amirhossein</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Berberine: A potential adjunct for the treatment of gastrointestinal cancers?</atitle><jtitle>Journal of cellular biochemistry</jtitle><addtitle>J Cell Biochem</addtitle><date>2018-12</date><risdate>2018</risdate><volume>119</volume><issue>12</issue><spage>9655</spage><epage>9663</epage><pages>9655-9663</pages><issn>0730-2312</issn><eissn>1097-4644</eissn><abstract>Gastrointestinal cancers are among the most prevalent cancers in the general population. Despite effective early diagnostics and intervention, the gastrointestinal cancer‐related mortality still remains elevated. Berberine (BBR) is a benzyl tetra isoquinoline alkaloid exracted from several plants. BBR is nontoxic to human normal cells, but suppresses the growth of different tumor cells: melanoma, epidermoid carcinoma, hepatoma, oral carcinoma, glioblastoma, prostatic carcinoma, and gastric carcinoma. In particular, BBR seems to suppress the proliferation of gastrointestinal cancers in a number of preclinical models. Several mechanisms of action have been hypothesized and demonstrated: immunomodulation, inhibition of topoisomerase enzymes, suppression of the EGF receptor, Her2/neu, and the VEGF receptor, induction of p53, Cip1/p21, Kip1/p27, Rb expression, induction of apoptosis (by regulation of MMPs pathway, caspases, Bax, and Smac/DIABLO), inhibition of arylamin N‐acetyltransferase activity, and regulation of microRNAs expression. The aim of this review is to summarize the pharmacological effects of BBR on animal and human gastrointestinal cancers. This review highlights the potential therapeutic role of berberine in gastrointestinal cancers. We have reviewed the molecular mechanisms of action of this alkaloid and the cellular targets through which berberine might exert its beneficial anti‐tumor effects.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>30125974</pmid><doi>10.1002/jcb.27392</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-8656-1444</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0730-2312
ispartof Journal of cellular biochemistry, 2018-12, Vol.119 (12), p.9655-9663
issn 0730-2312
1097-4644
language eng
recordid cdi_proquest_miscellaneous_2091235408
source Wiley
subjects Acetyltransferase
Apoptosis
Berberine
cancer
Cyclin-dependent kinase inhibitor p27
DIABLO protein
ErbB-2 protein
Gastric cancer
gastrointestinal tract
Glioblastoma
Hepatoma
Immunomodulation
Liver cancer
Melanoma
miRNA
Oral carcinoma
p53 Protein
Pharmacology
Prostate cancer
Tumor cells
Vascular endothelial growth factor
title Berberine: A potential adjunct for the treatment of gastrointestinal cancers?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T17%3A02%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Berberine:%20A%20potential%20adjunct%20for%20the%20treatment%20of%20gastrointestinal%20cancers?&rft.jtitle=Journal%20of%20cellular%20biochemistry&rft.au=Hesari,%20AmirReza&rft.date=2018-12&rft.volume=119&rft.issue=12&rft.spage=9655&rft.epage=9663&rft.pages=9655-9663&rft.issn=0730-2312&rft.eissn=1097-4644&rft_id=info:doi/10.1002/jcb.27392&rft_dat=%3Cproquest_cross%3E2129471086%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3532-90b40012e0a6bfd9abb088fb500343ec696b9f3bfd9a1c7cc9ffca23d4701c303%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2129471086&rft_id=info:pmid/30125974&rfr_iscdi=true